Caricamento...
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Schizophrenia affects approximately 1% of the population and continues to be associated with poor outcome because of the limited efficacy of and noncompliance with existing antipsychotic medications. An alternative hypothesis invoking the excitatory neurotransmitter, glutamate, arose out of clinical...
Salvato in:
| Pubblicato in: | Handb Exp Pharmacol |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2012
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4817347/ https://ncbi.nlm.nih.gov/pubmed/23027419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/978-3-642-25758-2_10 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|